BioPharma Credit (LSE:BPCR) Days Sales Outstanding: (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BPCR BioPharma Credit PLC LSE:BPCR
46 GF Score
Price $0.97
GF Value $0.82
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Days Sales Outstanding?

BioPharma Credit's average Accounts Receivable for the six months ended in Dec. 2025 was $0.0 Mil. BioPharma Credit's Revenue for the six months ended in Dec. 2025 was $63.1 Mil. Hence, BioPharma Credit's Days Sales Outstanding for the six months ended in Dec. 2025 was 0.00.

The historical rank and industry rank for BioPharma Credit's Days Sales Outstanding or its related term are showing as below:

LSE:BPCR's Days Sales Outstanding is not ranked *
in the Asset Management industry.
Industry Median: 45.63
* Ranked among companies with meaningful Days Sales Outstanding only.

BioPharma Credit's Days Sales Outstanding stayed the same from Dec. 2024 () to Dec. 2025 ().

BioPharma Credit  (LSE:BPCR) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

BioPharma Credit Days Sales Outstanding Related Terms

BioPharma Credit Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Days Sales Outstanding Chart

BioPharma Credit Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Sales Outstanding
Get a 7-Day Free Trial - - - - -

BioPharma Credit Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LSE:BPCR vs BLK, BX, KKR: Days Sales Outstanding Comparison

For the Asset Management subindustry, BioPharma Credit's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioPharma Credit Days Sales Outstanding vs Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's Days Sales Outstanding falls into.


LSE:BPCR
46GF Score
BioPharma Credit PLC LSE:BPCR
Days Sales Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

BioPharma Credit's Days Sales Outstanding for the fiscal year that ended in Dec. 2025 is calculated as

Days Sales Outstanding (A: Dec. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count ) / Revenue (A: Dec. 2025 )*Days in Period
=( ( + ) / 1 ) / 140.23100000016*365
=0 / 140.23100000016*365
=0.00

BioPharma Credit's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding (Q: Dec. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2025 ) + Accounts Receivable (A: Dec. 2025 )) / count ) / Revenue (A: Dec. 2025 )*Days in Period
=( ( + ) / 1 ) / 63.079000000637*365 / 2
=0 / 63.079000000637*365 / 2
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued. The current stock price of $0.97 is trading 18.3% above its estimated GF Value™ of $0.82. GuruFocus considers BioPharma Credit to be Modestly Overvalued.

Key valuation signals for LSE:BPCR:

  • Days Sales Outstanding:
  • GF Value™: $0.82 vs. price of $0.97 (18.3% above fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
46GF Score

Get the complete analysis for LSE:BPCR

Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price
$0.82
GF Value